×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
CYCC – cyclacel pharmaceuticals, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
CYCC
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
1/3
09:19 am
cycc
David Lazar acquires Cyclacel Pharmaceuticals preferred stock, becomes interim CEO; stock jumps [Seeking Alpha]
High
Report
David Lazar acquires Cyclacel Pharmaceuticals preferred stock, becomes interim CEO; stock jumps [Seeking Alpha]
1/3
09:01 am
cycc
Cyclacel Pharmaceuticals Announces Agreement for the Acquisition of Preferred Stock by David Lazar
High
Report
Cyclacel Pharmaceuticals Announces Agreement for the Acquisition of Preferred Stock by David Lazar
12/25
02:02 am
cycc
Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Medium
Report
Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
12/17
02:03 am
cycc
Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Low
Report
Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
12/9
02:02 am
cycc
Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Low
Report
Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
12/5
04:13 pm
cycc
Cyclacel Pharmaceuticals Announces Its Exploration of Potential Strategic Alternatives and Reduction of Operating Costs [Yahoo! Finance]
Low
Report
Cyclacel Pharmaceuticals Announces Its Exploration of Potential Strategic Alternatives and Reduction of Operating Costs [Yahoo! Finance]
12/5
04:05 pm
cycc
Cyclacel Pharmaceuticals Announces Its Exploration of Potential Strategic Alternatives and Reduction of Operating Costs
High
Report
Cyclacel Pharmaceuticals Announces Its Exploration of Potential Strategic Alternatives and Reduction of Operating Costs
12/1
03:05 am
cycc
Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Low
Report
Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Date
Time
Symbol
Company Name
Action
%Chg
11/12/2024
04:45 pm
cycc
cyclacel pharmaceuticals, inc.
BEAT
Report
11.2%
cyclacel pharmaceuticals, inc.
8/14/2024
04:05 pm
cycc
cyclacel pharmaceuticals, inc.
BEAT
Report
-9.6%
cyclacel pharmaceuticals, inc.
5/14/2024
04:05 pm
cycc
cyclacel pharmaceuticals, inc.
BEAT
Report
-11.3%
cyclacel pharmaceuticals, inc.
3/19/2024
04:05 pm
cycc
cyclacel pharmaceuticals, inc.
BEAT
Report
-4.3%
cyclacel pharmaceuticals, inc.
Date
Time
Symbol
Headline
Impact
12/12
04:15 pm
cycc
Form 8-K Cyclacel Pharmaceuticals For: Dec 06
Low
Report
Form 8-K Cyclacel Pharmaceuticals For: Dec 06
11/26
06:39 am
cycc
Form D Cyclacel Pharmaceuticals
Low
Report
Form D Cyclacel Pharmaceuticals
11/15
06:25 am
cycc
Form 8-K Cyclacel Pharmaceuticals For: Nov 13
Medium
Report
Form 8-K Cyclacel Pharmaceuticals For: Nov 13
11/14
07:22 pm
cycc
Form SC 13G/A Cyclacel Pharmaceuticals Filed by: Lind Global Fund II LP
Medium
Report
Form SC 13G/A Cyclacel Pharmaceuticals Filed by: Lind Global Fund II LP
11/14
03:27 pm
cycc
Form SC 13G Cyclacel Pharmaceuticals Filed by: ARMISTICE CAPITAL, LLC
Low
Report
Form SC 13G Cyclacel Pharmaceuticals Filed by: ARMISTICE CAPITAL, LLC
11/12
05:11 pm
cycc
Form 10-Q Cyclacel Pharmaceuticals For: Sep 30
High
Report
Form 10-Q Cyclacel Pharmaceuticals For: Sep 30
11/12
05:01 pm
cycc
Form 8-K Cyclacel Pharmaceuticals For: Nov 12
High
Report
Form 8-K Cyclacel Pharmaceuticals For: Nov 12
11/12
04:46 pm
cycc
Form 8-K Cyclacel Pharmaceuticals For: Nov 05
High
Report
Form 8-K Cyclacel Pharmaceuticals For: Nov 05
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
4/20
Cyclacel Pharmaceuticals Announces Collaboration With the University of Edinburgh to Study Its CDK Inhibitors to Reduce Runaway Inflammation in COVID-19 Disease
34.0%
12/9 Cyclacel’s CYC065 and Venetoclax Demonstrate Therapeutic Potential and Anticancer Activity in Acute Myeloid and Chronic Lymphocytic Leukemias 19.3%
9/4 Cyclacel Pharmaceuticals to Present at the 21st Annual H.C. Wainwright Global Investment Conference 10.5%
10/31 Form 8-K Cyclacel Pharmaceuticals For: Oct 28 10.3%
9/23 Cyclacel Pharmaceuticals to Present at the Ladenburg Thalmann 2019 Healthcare Conference 7.2%
8/13 Q2/2019 6/30/2019 EPS -0.110 ZacksConsensus -0.150 ActVsEst 0.040 - Beat 6.4%
3/18 Form 8-K Cyclacel Pharmaceuticals For: Mar 18 5.4%
3/17 Cyclacel Pharmaceuticals Inc (NASDAQ: CYCC) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. 5.3%
2/12 Form SC 13G Cyclacel Pharmaceuticals Filed by: RENAISSANCE TECHNOLOGIES LLC 4.2%
10/13 Here's Why We're Watching Cyclacel Pharmaceuticals's (NASDAQ:CYCC) Cash Burn Situation [Yahoo! Finance News] 3.7%
12/9 Cyclacel’s CYC065 and Venetoclax Demonstrate Therapeutic Potential and Anticancer Activity in Acute Myeloid and Chronic Lymphocytic Leukemias 19.3%
9/4 Cyclacel Pharmaceuticals to Present at the 21st Annual H.C. Wainwright Global Investment Conference 10.5%
10/31 Form 8-K Cyclacel Pharmaceuticals For: Oct 28 10.3%
9/23 Cyclacel Pharmaceuticals to Present at the Ladenburg Thalmann 2019 Healthcare Conference 7.2%
8/13 Q2/2019 6/30/2019 EPS -0.110 ZacksConsensus -0.150 ActVsEst 0.040 - Beat 6.4%
3/18 Form 8-K Cyclacel Pharmaceuticals For: Mar 18 5.4%
3/17 Cyclacel Pharmaceuticals Inc (NASDAQ: CYCC) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. 5.3%
2/12 Form SC 13G Cyclacel Pharmaceuticals Filed by: RENAISSANCE TECHNOLOGIES LLC 4.2%
10/13 Here's Why We're Watching Cyclacel Pharmaceuticals's (NASDAQ:CYCC) Cash Burn Situation [Yahoo! Finance News] 3.7%
TOP News Decliners
4/20
Form 8-K Cyclacel Pharmaceuticals For: Apr 19
-48.5%
3/13 Form S-1 Cyclacel Pharmaceuticals -27.1%
1/10 Form 8-K Cyclacel Pharmaceuticals For: Jan 10 -12.1%
2/26 Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results -11.7%
11/13 Form 10-Q Cyclacel Pharmaceuticals For: Sep 30 -11.3%
7/16 Cyclacel Pharmaceuticals Inc (NASDAQ: CYCC) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -10.7%
11/18 Cyclacel Pharmaceuticals Inc (NASDAQ: CYCC) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "strong-buy" rating. They now have a $0.50 price target on the stock. -10.2%
2/3 Cyclacel Pharmaceuticals to Present at the 2020 BIO CEO & Investor Conference -9.6%
5/31 Form 4 Cyclacel Pharmaceuticals For: May 29 Filed by: Spiegel Robert J. -9.2%
9/17 Form PRE 14A Cyclacel Pharmaceuticals For: Oct 28 -9.0%
3/13 Form S-1 Cyclacel Pharmaceuticals -27.1%
1/10 Form 8-K Cyclacel Pharmaceuticals For: Jan 10 -12.1%
2/26 Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results -11.7%
11/13 Form 10-Q Cyclacel Pharmaceuticals For: Sep 30 -11.3%
7/16 Cyclacel Pharmaceuticals Inc (NASDAQ: CYCC) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -10.7%
11/18 Cyclacel Pharmaceuticals Inc (NASDAQ: CYCC) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "strong-buy" rating. They now have a $0.50 price target on the stock. -10.2%
2/3 Cyclacel Pharmaceuticals to Present at the 2020 BIO CEO & Investor Conference -9.6%
5/31 Form 4 Cyclacel Pharmaceuticals For: May 29 Filed by: Spiegel Robert J. -9.2%
9/17 Form PRE 14A Cyclacel Pharmaceuticals For: Oct 28 -9.0%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: